Please use this identifier to cite or link to this item:
https://ahro.austin.org.au/austinjspui/handle/1/35339| Title: | Prevalence of cefixime-resistant Neisseria gonorrhoeae in Melbourne, Australia, 2021-2022. | Austin Authors: | Chow, Eric P F;Stevens, Kerrie;De Petra, Vesna;Chen, Marcus Y;Bradshaw, Catriona S;Sherry, Norelle L ;Barbee, Lindley A;Vodstrcil, Lenka A;Aguirre, Ivette;Seib, Kate L;Maddaford, Kate;Williamson, Deborah A;Howden, Benjamin P ;Fairley, Christopher K | Affiliation: | Melbourne Sexual Health Centre, Alfred Health, Melbourne, Victoria, Australia.;School of Translational Medicine, Faculty of Medicine, Nursing and Health Sciences, Monash University, Melbourne, Victoria, Australia.;Centre for Epidemiology and Biostatistics, Melbourne School of Population and Global Health, The University of Melbourne, Melbourne, Victoria, Australia. Microbiological Diagnostic Unit Public Health Laboratory, Department of Microbiology and Immunology, University of Melbourne, at the Peter Doherty Institute for Infection and Immunity, Melbourne, Victoria, Australia. Melbourne Sexual Health Centre, Alfred Health, Melbourne, Victoria, Australia.;Microbiological Diagnostic Unit Public Health Laboratory, Department of Microbiology and Immunology, University of Melbourne, at the Peter Doherty Institute for Infection and Immunity, Melbourne, Victoria, Australia. Infectious Diseases Microbiological Diagnostic Unit Public Health Laboratory, Department of Microbiology and Immunology, University of Melbourne, at the Peter Doherty Institute for Infection and Immunity, Melbourne, Victoria, Australia.;Department of Infectious Diseases & Immunology, Austin Health, Heidelberg, Victoria, Australia. Department of Medicine, University of Washington, Seattle, Washington, USA.;Public Health - Seattle & King County, HIV/STD Program, Seattle, Washington, USA. Melbourne Sexual Health Centre, Alfred Health, Melbourne, Victoria, Australia.;School of Translational Medicine, Faculty of Medicine, Nursing and Health Sciences, Monash University, Melbourne, Victoria, Australia.;Centre for Epidemiology and Biostatistics, Melbourne School of Population and Global Health, The University of Melbourne, Melbourne, Victoria, Australia. Institute for Glycomics, Griffith University, Southport, Queensland, Australia. Melbourne Sexual Health Centre, Alfred Health, Melbourne, Victoria, Australia.;School of Translational Medicine, Faculty of Medicine, Nursing and Health Sciences, Monash University, Melbourne, Victoria, Australia. Victorian Infectious Disease Reference Laboratory, The Royal Melbourne Hospital, at The Peter Doherty Institute for Infection and Immunity, Melbourne, Victoria, Australia.;Department of Infectious Diseases, University of Melbourne, at the Peter Doherty Institute for Infection and Immunity, Melbourne, Victoria, Australia.;Walter and Eliza Hall Institute, Melbourne, Victoria, Australia. Microbiological Diagnostic Unit Public Health Laboratory, Department of Microbiology and Immunology, University of Melbourne, at the Peter Doherty Institute for Infection and Immunity, Melbourne, Victoria, Australia.;Department of Infectious Diseases & Immunology, Austin Health, Heidelberg, Victoria, Australia.;Centre for Pathogen Genomics, University of Melbourne, Melbourne, Victoria, Australia. Melbourne Sexual Health Centre, Alfred Health, Melbourne, Victoria, Australia.;School of Translational Medicine, Faculty of Medicine, Nursing and Health Sciences, Monash University, Melbourne, Victoria, Australia. |
Issue Date: | 15-Jun-2024 | Date: | 2024 | Publication information: | The Journal of Infectious Diseases 2024-06-15 | Abstract: | While ceftriaxone remains the first-line treatment for gonorrhoea, the US CDC recommended cefixime as a second-line treatment in 2021. We tested 1176 Neisseria gonorrhoeae isolates among clients attending the Melbourne Sexual Health Centre in 2021-2022. The prevalence of cefixime resistance was 6.3% (74/1176), azithromycin resistance was 4.9% (58/1176) and ceftriaxone resistance was 0% (0/1176). Cefixime resistance was the highest among women (16.4%, 10/61), followed by men-who-have-sex-with-women (6.4%, 7/109), and men-who-have-sex-with-men (5.8%, 57/982). The prevalence of cefixime-resistant N. gonorrhoeae exceeds the threshold of the 5% resistance level recommended by the World Health Organization; and thus, cefixime treatment would have limited benefits in Australia. | URI: | https://ahro.austin.org.au/austinjspui/handle/1/35339 | DOI: | 10.1093/infdis/jiae313 | ORCID: | 0000-0003-1766-0657 0000-0002-6643-5678 |
Journal: | The Journal of Infectious Diseases | PubMed URL: | 38877763 | ISSN: | 1537-6613 | Type: | Journal Article | Subjects: | Gonorrhoea Neisseria gonorrhoeae antimicrobial resistance resistance treatment |
| Appears in Collections: | Journal articles |
Show full item record
Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.